Genmab A/S

GMAB· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$28.68-0.66%

2026-08-03

Valuation Metrics

Genmab A/S's Market Cap is $17.61B. At end of 2025 it was $18.98B. Ranked #657 of 3,112 in US market (top 21%), #199 of 1,445 on NASDAQ (top 14%), #30 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 11%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$17.61B	US#657/3,112 Sec#30/269
Revenue	$3.90B	US#1,059/3,112 Sec#31/269
Net Income	$821M	US#608/3,112 Sec#25/269
Total Assets	$12.38B	US#862/3,112 Sec#26/269
Net Assets	$5.68B	US#639/3,112 Sec#29/269
Value
P/E	21.45x	US#1,103/3,112 Sec#39/269
P/B	3.10x	US#1,710/3,112 Sec#90/269
PEG	0.25x	US#372/3,112 Sec#18/269
P/S	4.51x	US#2,187/3,112 Sec#73/269
EV/EBITDA	17.34x	US#1,696/3,112 Sec#49/269
FCF Yield	4.95%	US#1,293/3,112 Sec#46/269
Profitability
ROE	14.45%	US#916/3,112 Sec#47/269
ROA	6.63%	US#788/3,112 Sec#44/269
Op. Margin	32.99%	US#355/3,112 Sec#20/269
Revenue Growth	754.59%	US#31/3,112 Sec#13/269
Earnings Growth	85.35%	US#402/3,112 Sec#17/269
Financial Health
Debt Ratio	117.81%	US#1,239/3,112 Sec#174/269
Total Debt	$5.35B	US#625/3,112 Sec#24/269
FCF	$871M	US#621/3,112 Sec#26/269
Cash	$1.52B	US#523/3,112 Sec#27/269
Current Ratio	2.18x	US#1,139/3,112 Sec#219/269
Net Debt/EBITDA	3.10x	US#1,688/3,112 Sec#72/269
Performance
1Y Return	31.68%	US#1,189/3,112 Sec#144/269
1M Return	0.56%	US#1,565/3,112 Sec#67/269
From 52W High	-19.05%	US#1,663/3,112 Sec#104/269
1Y MDD	-32.51%	US#1,551/3,112 Sec#99/269
Trading
Volume	1,732,467 shares	US#1,013/3,112 Sec#92/269
Trading Value	$49M	US#1,368/3,112 Sec#87/269
Per Share
EPS	$4.47	US#718/3,112 Sec#20/269
BPS	$9.47	US#1,828/3,112 Sec#68/269